Dossier assessment
Crizotinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Crizotinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Crizotinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Added benefit of crizotinib is not proven
Hints of better quality of life, but also of more frequent, sometimes serious, side effects
Additional information
Federal Joint Committee (G-BA)
2013-05-02 A G-BA decision was published.
Project details
- Project no.
- A12-15
- Commission
- Commission awarded on 15.11.2012 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Crizotinib (lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Crizotinib (NSCLC) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Crizotinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed